반려동물 골관절염 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 동물별, 투여 경로별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Companion Animal Osteoarthritis Market Summary

The global companion animal osteoarthritis market size was estimated at USD 2.29 billion in 2024 and is projected to reach USD 13.27 billion by 2033, growing at a CAGR of 23.5% from 2025 to 2033. Key factors expected to drive the market include the rising prevalence of osteoarthritis, increasing R&D initiative, emerging novel treatments, increasing awareness campaigns, and advancing diagnostic techniques increasing adoption of osteoarthritis (OA) treatment.

The rising prevalence of osteoarthritis (OA) in companion animals-particularly dogs, cats, and horses-is significantly driving the global companion animal osteoarthritis market. In canines alone, estimates suggest that approximately 20% of dogs over one year of age show clinical signs of OA, and this prevalence can escalate to as high as 80% in older dogs, according to both clinical observations and radiographic studies. Similar trends are observed in felines, where OA is often underdiagnosed but increasingly recognized in aging cat populations, with some studies indicating radiographic signs in up to 90% of cats over 12 years old. Equine OA also remains a leading cause of reduced performance and early retirement, especially in sport and racehorses.

Several factors are contributing to this increase in OA prevalence, including extended pet lifespans due to advances in nutrition and veterinary care, rising rates of obesity (a major OA risk factor), and improved awareness and diagnostic capabilities among veterinarians and pet owners. These trends are expanding the demand for early diagnosis, chronic disease management, and pain relief solutions.

This growing burden has catalyzed significant investment and innovation in OA therapeutics, including the development of novel biologics, regenerative therapies (e.g., stem cells and PRP), monoclonal antibodies (such as Zoetis' Librela and Solensia), and other multimodal pain management approaches. Pharmaceutical and biotech companies are actively developing long-acting, targeted therapies that offer better compliance and improved quality of life for pets, particularly as pet owners increasingly seek premium and preventative care. In parallel, the surge in veterinary visits and emphasis on mobility monitoring and wellness programs is reinforcing a robust market for diagnostics, supplements, joint-support diets, and rehabilitation services.

Altogether, these epidemiological and behavioral factors are not only expanding the companion animal OA patient pool but are also transforming the disease into a cornerstone segment of the global animal health industry-creating long-term growth opportunities across therapeutics, diagnostics, and supportive care solutions.

Despite strong market performance and widespread adoption of OA-targeting monoclonal antibodies like Librela, the recent public controversy-including calls for outright bans and new data suggesting a nine fold increase in musculoskeletal adverse events-poses a reputational and regulatory challenge. Heightened scrutiny from regulators like the FDA and EMA may result in tougher post market surveillance, label revisions, or prescribing restrictions. In the short term, veterinarians and pet owners might pivot toward more conservative options, such as established NSAIDs or supplements, potentially slowing growth in the biologics segment. However, transparent safety studies, improved pharmacovigilance, and clear risk-benefit guidelines could restore confidence and ultimately solidify the position of mAb therapies as a premium OA treatment-assuming manufacturers respond proactively

Global Companion Animal Osteoarthritis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the companion animal osteoarthritis market report based on product, animal, route of administration, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
  • Stem Cells
  • Platelet-Rich Plasma (PRP)
  • Monoclonal Antibodies (mAb)
  • Other Biologics
• Viscosupplements
• Pharmaceuticals
  • Steroids
  • NSAIDS
  • Others
• Nutritional Supplements
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Canine
• Equine
• Feline
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
  • Intra-muscular
  • Intra-articular
  • Other Injectable
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals/Clinics
• E-commerce
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Global Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Companion Animal Osteoarthritis Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence of Osteoarthitis
    • 3.2.1.2. Increasing R&D Initiatives
    • 3.2.1.3. Emerging Novel Treatments
    • 3.2.1.4. Increasing Awareness Campaigns
    • 3.2.1.5. Advancing Diagnostic Techniques Increasing Adoption of OA Treatment
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory Hurdles
    • 3.2.2.2. Emerging Adverse Drug Reactions (ADR)
    • 3.2.2.3. Stringent Regulations
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Companion Animal Osteoarthritis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
  • 3.3.3. Regulatory Framework by Key Countries
  • 3.3.4. Estimated Animal Population, by Key Species, by Key Countries, 2021-2024
  • 3.3.5. Pipeline/ Clinical Trials Analysis
  • 3.3.6. COVID-19 Impact Analysis

Chapter 4. Companion Animal Osteoarthritis Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Companion Animal Osteoarthritis Market: Product Movement Analysis
• 4.3. Companion Animal Osteoarthritis Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
• 4.4. Biologics
  • 4.4.1. Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Stem Cells
    • 4.4.2.1. Stem Cells Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Platelet-Rich Plasma (PRP)
    • 4.4.3.1. Platelet-Rich Plasma (PRP) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Monoclonal Antibodies (mAb)
    • 4.4.4.1. Monoclonal Antibodies (mAb) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Other Biologics
    • 4.4.5.1. Other Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Viscosupplements
  • 4.5.1. Viscosupplements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Pharmaceuticals
  • 4.6.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Steroids
    • 4.6.2.1. Steroids Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. NSAIDs
    • 4.6.3.1. NSAIDs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Others
    • 4.6.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Nutritional Supplements
  • 4.7.1. Nutritional Supplements Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Companion Animal Osteoarthritis Market: Animal Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Companion Animal Osteoarthritis Market: Animal Movement Analysis
• 5.3. Companion Animal Osteoarthritis Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
• 5.4. Canine
  • 5.4.1. Canine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Feline
  • 5.5.1. Feline Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Equine
  • 5.6.1. Equine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Companion Animal Osteoarthritis Market: By Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Companion Animal Osteoarthritis Market: By Route of Administration Movement Analysis
• 6.3. Companion Animal Osteoarthritis Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
  • 6.3.1. Oral
    • 6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Injectables
    • 6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Intra-muscular
    • 6.3.3.1. Intra-muscular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Intra-articular
    • 6.3.4.1. Intra-articular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.5. Other Injectables
    • 6.3.5.1. Other Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.6. Others
    • 6.3.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Companion Animal Osteoarthritis Market: By End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Companion Animal Osteoarthritis Market: By End Use Movement Analysis
• 7.3. Companion Animal Osteoarthritis Market Size & Trend Analysis, by end use, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Hospitals/Clinics
    • 7.3.1.1. Veterinary Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. E-commerce
    • 7.3.2.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Others
    • 7.3.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Companion Animal Osteoarthritis Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Companion Animal Osteoarthritis Market Share, By Region, 2024 & 2033 (USD Million)
• 8.3. Regional Outlook
• 8.4. North America
  • 8.4.1. North America Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. U.S. Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Canada Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Mexico Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. UK Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Germany Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. France Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Italy Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Spain Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Denmark Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Sweden Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Norway Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Japan Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. China Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. India Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Australia Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. South Korea Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Thailand Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Brazil Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Argentina Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East & Africa
  • 8.8.1. Middle East & Africa Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. South Africa Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Saudi Arabia Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. UAE Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Kuwait Companion Animal Osteoarthritis Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heap Map Analysis
• 9.3. Company Profiles
  • 9.3.1. Zoetis
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Boehringer Ingelheim
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Elanco Animal Health
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. American Regent, Inc.
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Merck Animal Health (Merck & Co. Inc)
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Vetoquinol S.A.
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Ceva Sante Animale
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Virbac
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Biogenesis Bago
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Ardent Animal Health, Llc
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. PetVivo Holdings, Inc. (Spryng)
    • 9.3.11.1. Participant's Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. VetStem Inc.
    • 9.3.12.1. Participant's Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Product Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Enso Discoveries
    • 9.3.13.1. Participant's Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Product Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Contura Vet US
    • 9.3.14.1. Participant's Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Product Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. T-Cyte Therapeutics
    • 9.3.15.1. Participant's Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Product Benchmarking
    • 9.3.15.4. Strategic Initiatives
  • 9.3.16. Medrego Llc.
    • 9.3.16.1. Participant's Overview
    • 9.3.16.2. Financial Performance
    • 9.3.16.3. Product Benchmarking
    • 9.3.16.4. Strategic Initiatives
• 9.4. Strategy Mapping
  • 9.4.. Mergers & Acquisitions
  • 9.4.2. Partnerships & Collaborations
  • 9.4.3. Expansion
  • 9.4.4. Product launch
  • 9.4.5. Product Approval
  • 9.4.6. Others
• 9.5. List of Key Companies
  • 9.5.1. List of Manufacturers
  • 9.5.2. List of Distributors